2 completed, 1 recruiting, 1 terminated. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
Follow etripamil: new trials by email Literature Review of etripamil trials Research Report on etripamil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 Placebo, Etripamil - Atrial Fibrillation | Phase 3 | Recruiting | Milestone Pharmaceuticals Inc. | 750 | 2026-08-20 | 2026-10-07 |
| ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2 Etripamil, Placebo - Atrial Fibrillation | Phase 2 | Completed | Milestone Pharmaceuticals Inc. | 69 | 2020-11-19 | 2024-09-19 |
| Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil, Placebo, Etripamil Test Dose - Paroxysmal Supraventricular Tachycardia | Phase 3 | Terminated | Milestone Pharmaceuticals Inc. | 1097 | 2018-06-18 | 2024-07-12 |
| Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm Etripamil, Placebo - Paroxysmal Supraventricular Tachycardia (PSVT) | Phase 2 | Completed | Milestone Pharmaceuticals Inc. | 199 | 2015-03-27 | 2020-12-30 |
Atrial Fibrillation (2) · Tachycardia, Ventricular (2) · Tachycardia, Atrioventricular Nodal Reentry (1)
Milestone Pharmaceuticals Inc. (4)
Canada (4) · Netherlands (3) · United States (3) · Belgium (1) · France (1) · Germany (1) · Hungary (1) · Poland (1) · Spain (1)
David Bharucha, MD (1) · Denis Roy, M.D (1) · Francis Plat (1) · James E. Ip, MD (1)
PMID 30049309, PMID 35728658, PMID 36441560, PMID 37331368, PMID 37950726
2018 (1)